Ustekinumab for the treatment of psoriatic arthritis: an update

Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale ran...

Descripción completa

Detalles Bibliográficos
Autores principales: Davari, Parastoo, Leo, Michael S, Kamangar, Faranak, Fazel, Nasim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158889/
https://www.ncbi.nlm.nih.gov/pubmed/25214798
http://dx.doi.org/10.2147/CCID.S50003
_version_ 1782334133039529984
author Davari, Parastoo
Leo, Michael S
Kamangar, Faranak
Fazel, Nasim
author_facet Davari, Parastoo
Leo, Michael S
Kamangar, Faranak
Fazel, Nasim
author_sort Davari, Parastoo
collection PubMed
description Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.
format Online
Article
Text
id pubmed-4158889
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-41588892014-09-11 Ustekinumab for the treatment of psoriatic arthritis: an update Davari, Parastoo Leo, Michael S Kamangar, Faranak Fazel, Nasim Clin Cosmet Investig Dermatol Review Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis. Dove Medical Press 2014-09-02 /pmc/articles/PMC4158889/ /pubmed/25214798 http://dx.doi.org/10.2147/CCID.S50003 Text en © 2014 Davari et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Davari, Parastoo
Leo, Michael S
Kamangar, Faranak
Fazel, Nasim
Ustekinumab for the treatment of psoriatic arthritis: an update
title Ustekinumab for the treatment of psoriatic arthritis: an update
title_full Ustekinumab for the treatment of psoriatic arthritis: an update
title_fullStr Ustekinumab for the treatment of psoriatic arthritis: an update
title_full_unstemmed Ustekinumab for the treatment of psoriatic arthritis: an update
title_short Ustekinumab for the treatment of psoriatic arthritis: an update
title_sort ustekinumab for the treatment of psoriatic arthritis: an update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158889/
https://www.ncbi.nlm.nih.gov/pubmed/25214798
http://dx.doi.org/10.2147/CCID.S50003
work_keys_str_mv AT davariparastoo ustekinumabforthetreatmentofpsoriaticarthritisanupdate
AT leomichaels ustekinumabforthetreatmentofpsoriaticarthritisanupdate
AT kamangarfaranak ustekinumabforthetreatmentofpsoriaticarthritisanupdate
AT fazelnasim ustekinumabforthetreatmentofpsoriaticarthritisanupdate

Ejemplares similares